Moderna
5 statements across 5 episodes · 1 bullish · 0 bearish · 4 people on the record · first statement Apr 27, 2023 by Elad Gil · said 12 times in 6 episodes since 2023 · across every show →
Mentions by year
brought up most by Sarah Guo (4), Noubar Afeyan (3), Sajith Wickramasekara (2), Elad Gil (2), Jakob Uszkoreit (1)
tap a year for its mentions
2025 10 mentions in 4 episodes 3 per episode
- No Priors Ep. 104 | With Flagship Pioneering CEO and Co-Founder Noubar Afeyan
- No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara
- No Priors Ep. 138 | The Best of 2025 (So Far) with Sarah Guo and Elad Gil
- No Priors Ep. 116 | With Sarah and Elad
- every mention in 2025, scene by scene →
2023 2 mentions in 2 episodes 1 per episode
Everything said about Moderna, oldest first
Apr 27, 2023 neutral
Gil: No major drug-developing biotech founded since late 1980s hit $30B-$50B
“The last time a biotech company hit, I don't know what it is, 3040, fifty billion dollars in market cap, something like that. The last year such a thing was founded was in the late eighties. So it's been at this point, what is that? 35, 40 years without a new …”
Aug 24, 2023 bullish
Feb 27, 2025 neutral
Afeyan: When Flagship started Moderna, no other companies were developing mRNA therapeutics
“MRNA, which was our 18th company that became Moderna is a good example of this. There was no mRNA drug or vaccine before. There was nobody working on it. When we started, there were academic labs that had worked on it and given up.”
May 29, 2025
Gil: No $50B+ biotech started since the 1980s, excluding Moderna
“The last time a fifty billion dollar plus biotech company was started from scratch, excluding Moderna, which was kind of an accident of COVID, was in the eighties. I think it was Regeneron. And so it's been almost 40 years since we've had a de novo, like tens …”
Nov 13, 2025
Benchling serves 1,300 biopharma companies and 7,000 academic institutions
“Today we work with about 1300 biotech and pharma companies scientists at over 7000 academic institutions, universities, all, all around the world. And our software powers, you know, household names like Moderna and Sanofi and Eli Lilly and Regeneron, but also …”